Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Revenue (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Revenue for 7 consecutive years, with $75000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Revenue rose 52716.9% to $75000.0 in Q2 2022 year-over-year; TTM through Mar 2023 was $75000.0, a 28.11% decrease, with the full-year FY2025 number at $10.8 million, changed N/A from a year prior.
  • Revenue was $75000.0 for Q2 2022 at Crescent Biopharma, up from $17625.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $9.0 million in Q1 2020 to a low of $142.0 in Q2 2021.
  • A 3-year average of $1.4 million and a median of $124747.5 in 2020 define the central range for Revenue.
  • Peak YoY movement for Revenue: tumbled 91.34% in 2021, then skyrocketed 52716.9% in 2022.
  • Crescent Biopharma's Revenue stood at $162935.0 in 2020, then tumbled by 89.18% to $17625.0 in 2021, then surged by 325.53% to $75000.0 in 2022.
  • Per Business Quant, the three most recent readings for CBIO's Revenue are $75000.0 (Q2 2022), $17625.0 (Q4 2021), and $86560.0 (Q3 2021).